Related Experiment Video
Updated: Jul 5, 2026

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
Published on: July 18, 2019
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis
Craig D Fisher1, Jonathan P Jackson, Andrew J Lickteig
1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 1703 East Mabel, Tucson, AZ 85721, USA. cfisher@pharmacy.arizona.edu
Abstract:
Non-alcoholic steatohepatitis (NASH) is a disease that compromises hepatic function and the capacity to metabolize numerous drugs. Aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-activated receptor alpha (PPARalpha), and nuclear factor-E2 related factor 2 (Nrf2) are xenobiotic activated transcription factors that regulate induction of a number of drug metabolizing enzymes (DMEs). The purpose of the current study was to determine whether experimental NASH alters the xenobiotic activation of these transcription factors and induction of downstream DME targets Cyp1A1, Cyp2B10, Cyp3A11, Cyp4A14 and NAD(P)H:quinone oxidoreductase 1 (Nqo1), respectively. Mice fed normal rodent chow or methionine-choline-deficient (MCD) diet for 8 weeks were then treated with microsomal enzyme inducers beta-naphoflavone (BNF), 1,4-bis-[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), pregnenolone-16alpha-carbonitrile (PCN), clofibrate (CFB) or oltipraz (OPZ), known activators of AhR, CAR, PXR, PPARalpha and Nrf2, respectively. Results of this study show that (1) Hepatic PXR mRNA levels were significantly increased (1.4-fold) in mice fed MCD diet, while AhR, CAR, PPARalpha and Nrf2 were not affected. (2) The MCD diet did not alter hepatic inducibility of Cyp1A1, Cyp2B10, Cyp3A11 mRNA levels by their respective microsomal inducers. (3) Constitutive levels of Cyp4A14 mRNA were significantly increased in mice fed the MCD diet, yet further induction by clofibrate was not observed. (4) Hepatic Nqo1 mRNA levels were significantly increased by the MCD diet; however, additional induction of Nqo1 was still achievable following treatment with the Nrf2 activator OPZ.
Insights
Non-alcoholic steatohepatitis (NASH) alters drug metabolism by increasing pregnane X receptor (PXR) and NAD(P)H:quinone oxidoreductase 1 (Nqo1) levels. However, induction of other drug-metabolizing enzymes remains largely unaffected in this disease model.
Area of Science:
- Pharmacology
- Hepatology
- Biochemistry
Background:
- Non-alcoholic steatohepatitis (NASH) impairs liver function and drug metabolism.
- Xenobiotic-activated transcription factors (AhR, CAR, PXR, PPARalpha, Nrf2) regulate drug-metabolizing enzymes (DMEs).
Purpose of the Study:
- To investigate how experimental NASH affects xenobiotic transcription factor activation.
- To determine the impact of NASH on downstream DME induction.
Main Methods:
- Mice were fed a methionine-choline-deficient (MCD) diet to induce NASH.
- Mice were treated with specific inducers for AhR, CAR, PXR, PPARalpha, and Nrf2.
- mRNA levels of transcription factors and DMEs (Cyp1A1, Cyp2B10, Cyp3A11, Cyp4A14, Nqo1) were analyzed.
Main Results:
- Hepatic PXR mRNA levels increased significantly in MCD diet-fed mice.
- MCD diet did not alter inducibility of Cyp1A1, Cyp2B10, Cyp3A11 by their inducers.
- Constitutive Cyp4A14 mRNA increased, but further induction by clofibrate was not observed.
- Hepatic Nqo1 mRNA increased with the MCD diet, and further induction by oltipraz was possible.
Conclusions:
- Experimental NASH significantly upregulates hepatic PXR and constitutive Cyp4A14 and Nqo1 mRNA levels.
- The inducibility of key drug-metabolizing enzymes Cyp1A1, Cyp2B10, and Cyp3A11 by their respective activators is not compromised by NASH.
- NASH affects Nqo1 expression, but its inducibility by Nrf2 activators remains intact.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Metabolism: Phase I Reactions
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacogenetics of Drug Metabolism: Overview
Hepatic Drug Excretion: Influencing Factors

